Register
Login:
Share:
Email Facebook Twitter


Market analyst Rajan Dhall talks about the financial market


Futura Medical Share Chat (FUM)



Share Price: 52.75Bid: 51.50Ask: 54.00Change: 0.00 (0.00%)No Movement on Futura Med.
Spread: 2.50Spread as %: 4.85%Open: 52.75High: 52.75Low: 52.75Yesterday’s Close: 52.75


Share Discussion for Futura Medical


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


daringinvestor
Posts: 15
Off Topic
Opinion:No Opinion
Price:53.00
MED2002 market
Tue 21:50
A post from iii regarding the market for med2002. I think what is being stated is that the DRG forecast for prescription sales could be blown out of the water IF the phase 3 trials are a success across the whole spectrum of ED with a good safety profile. GIven that the phase 3 trials are being planned for several strength doses of med2002, it improves the chances of success....

"A bit confused as to the numbers for med2002.

Global ED market is worth approx 5 billion dollars.

7.5 percent of ED patients can't take PDe5 inhibitors due to contraindications with other medicines. This prescription market alone is worth approx 375 million dollars.
The forecasts done by DRG for the prescription market states sales of 600 million dollars.

However on Futura's website it also states a 30 % market share of the prescription market is possible (however this depends on how well med2002 works across all spectrums of ED sufferers).
Clearly the prescription market figures do not represent a 30 percent market share. In fact it represents a 12 percent market share.
If med2002 is indeed shown in the higher strength dose to be just as good for the severe ED cases AND safe, then it will well def be a first line of therapy and truly mean big numbers. 30 percent market share is the equivalent of 1.5 billion dollars. Plus 500 million for over the counter meaning 2 billion dollar peak sales.
Yes well and truly A huge number but first things first... we need excellent phase 3 trials"
 
GCCRa
Posts: 479
Off Topic
Opinion:Strong Buy
Price:53.00
RE: Yeh but
Mon 20:19
I don't think i'd argue with your patience point. I don't expect to be making the serious four fold profits I expect for a year or two. i do though expect more transparency. Sure some info is commercially confidential, but not all numbers surely.
Chrisjc
Posts: 35
Off Topic
Opinion:No Opinion
Price:53.75
Yeh but
22 Jun '17
I agree with you daringinvestor patience is the key, ok difficult when you see all the pluses for this company, but it's the only way to get the best deal. I feel glad that we don't have the government doing our negotiations, at least we have a knowledgable and dedicated team who are ALL working for the same cause!
daringinvestor
Posts: 15
Off Topic
Opinion:No Opinion
Price:53.75
RE: Yeh but
22 Jun '17
Back when the Med2002 results were announced I got shot down on this board when I said patience was needed...that it would be some time before we see the fruits...

People are getting impatient however you need to remember Futura Medical cannot disclose commercially sensitive information for partners regarding launch dates. Yes some big news expected this year the biggest one will be med2002 deal. This will have some significant payments attached to it so I'm the mean time relax and carry on. It'll take time but these things do. Negotiations always take time.
GCCRa
Posts: 479
Off Topic
Opinion:Strong Buy
Price:53.75
RE: Yeh but
22 Jun '17
Yes, I tend to agree Suark, I DO think this is one of the most promising shares out there but there is a need to publish some hard facts too. If all they say is borne out with hard numbers I can't see us staying independent for too long. That Viagra subsitute on it's own would indicate massive upside.
Suark
Posts: 37
Off Topic
Opinion:No Opinion
Price:53.75
Yeh but
22 Jun '17
Stoneyd thanks for reply, but I was aware of y/e 2016 results. It's now nearly 6 months on! How about saying by how much sales of the condom have increased. Saying they have reordered means nothing. From what base . 100 or 100000! Also have we now got regulatory approval from the EU. They said they will be selling in Portugal so why not the rest of Europe and especially the UK . I'm not trying to diss this co. It has massive potential, but I want some hard facts not wishy you washy statements.
B2HS2L
Posts: 69
Observation
Opinion:Weak Buy
Price:55.00
share price
20 Jun '17
getting hit, MM's needing your shares? - News must be in the offing.
sp needs to be a little lower to be a good buying opportunity.
StoneyD
Posts: 2,582
Off Topic
Opinion:No Opinion
Price:57.00
RE: End of year results
19 Jun '17
Suark
Posts: 37
Off Topic
Opinion:No Opinion
Price:57.00
End of year results
19 Jun '17
Can't work out this co. Why no financial report,ie money received in up front payments, sales of the condom which they have said are going well, cash burn? It may be commercially sensitive but a total amount wouldn't give too much away. Also how can a co. With less than 10 employees come up with 3 novel products when big pharma cannot. The directors seem very good at giving themselves share options then immediately selling them . Doesn't inspire confidence in me. Hope someone can put my mind at ease.
alexia93
Posts: 1,401
Off Topic
Opinion:No Opinion
Price:57.00
All things.......
16 Jun '17
Come to those that wait.....Lets hope that rings true with FUM. I'm substantially invested here relative to the rest of my portfolio and consider that the present sp should rise dramatically after the next positive RNS. imo. GLA




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.